HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

485.171

+2.8150.58%

Number of Gainers:21

Number of Losers:10

Number of Flat:2

PE:- -

High:489.931

Open:482.072

Low:481.405

Close:482.357

Volume:61.61M

Turnover:1.28B

Market Cap:307.98B

Float Cap:273.83B

Loading ...

Hong Kong Stock Market Highlights: JXR Advances Female Health Translational Medicine Platform

AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

Hbm Holdings Says Solstice Oncology Launches Series a Financing Round

Pharmaceutical Firms Divest Assets to Bolster Core Operations

Lee's Pharm Secures Exclusive Rights to Develop and Market Novel PARP1 Inhibitor Across Greater China and Southeast Asia

Trump Unveils Midterm Strategy: Tax Cuts and "MAHA Movement" Take Center Stage, Targeting Pharma and Processed Food Sectors

Everest Medicines Unit Enters Supply, Distribution Cooperation Contract

MT Newswires Live

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion

Genfleet-B Repurchases 75,000 Shares for HK$1.96 Million on September 9

HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations

HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer

Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

THOMSON REUTERS

Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round

THOMSON REUTERS

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal

BOC International sees pharma sector earnings recovery as industry enters a reversal cycle

HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BK1574/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":485.17123,"timestamp":1789632487194,"preClose":482.35672,"halted":0,"volume":61610930,"delay":0,"changeRate":0.005835,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":2.814514,"latestTime":"09-17 16:00:00","open":482.07187,"high":489.93134,"low":481.40475,"amount":1281540013.5,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.002293,"increases":18,"decrements":10,"flats":4,"marketCap":307980316848,"floatMarketCap":273827471128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.93134,"amplitude":0.017677,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":485.17123,"volume":61610930,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.002293,"peRate":160.310337,"marketCap":307980316848,"floatMarketCap":273827471128,"timestamp":1789632487194,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":10,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171834211","title":"Hong Kong Stock Market Highlights: JXR Advances Female Health Translational Medicine Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1171834211","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171834211?lang=en_us&edition=fundamental","pubTime":"2026-09-10 09:04","pubTimestamp":1789002291,"startTime":"0","endTime":"0","summary":"JXR (01951) announced plans to further develop a translational medicine platform primarily focused on female health, marking a strategic move to strengthen its presence in this specialized...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1574","02142","BK4585","FHCO","00950","00580","BK1219","BK1191","BK1161","01951","BK1583","KCAI","BK1189","BK4588","VXUS","BK1116","06681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103728541","title":"AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1103728541","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103728541?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:26","pubTimestamp":1789000007,"startTime":"0","endTime":"0","summary":"INSILICO (03696) has announced that its lead artificial intelligence-powered investigational drug, Rentosertib (also known as ISM001-055/INS018_055), has achieved a significant clinical milestone...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03086","161631","07266","AGIX","PSQ","LCLG","QTOC","TECY","KOMP","WPAI","QSWN","09086","CHAT","MEDX","NEWZ","AIBU","TQQY","NAPR","MVPS","NOCT","QID","03696","159992","03034","IBBQ","AIQU","IBBJ","QQQM","AIFD","BK1161","TQQQ","QDEC","QLD","PBOT","OGIG","09834","BK1141","MDTX","QMAR","02834","06978","CWC","CPNQ","FWD","QQQ","GK","07568","03455","QQQX","GPIQ","DQJN","NJAN","PSYK","TARK","BK1574","07261","07522","ARTY","MFIG","LNGR","VUSE","QQA","NJUL","NBDS","BK4593","SQQQ","BMED","AQGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","01302","BK1583","PTH","09996","HART","RSPH","BK1600","AGNG","GDOC","159883","LGHT","BK1100","MDEV","IEIH","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666753136","title":"Hbm Holdings Says Solstice Oncology Launches Series a Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2666753136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666753136?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:20","pubTimestamp":1788967253,"startTime":"0","endTime":"0","summary":"Sept 9 (Reuters) - Hbm Holdings Ltd <2142.HK>::*SOLSTICE ONCOLOGY LAUNCHES $225 MILLION SERIES A FINANCING ROUND*Further company coverage: 2142.HK* ((Reuters.Briefs@thomsonreuters.com;))((Reuters Inve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nRSD12sC1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169429326","title":"Pharmaceutical Firms Divest Assets to Bolster Core Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1169429326","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169429326?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:12","pubTimestamp":1788966731,"startTime":"0","endTime":"0","summary":"A growing number of domestic listed pharmaceutical companies have recently disclosed asset disposal announcements, planning to sell partial or full equity stakes in their controlled subsidiaries....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","FOSL","BK4202","BK1161","02196","BK1574","BK1593","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183555429","title":"Lee's Pharm Secures Exclusive Rights to Develop and Market Novel PARP1 Inhibitor Across Greater China and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=1183555429","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183555429?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:40","pubTimestamp":1788964828,"startTime":"0","endTime":"0","summary":"Lee's Pharm (00950) has announced that its wholly-owned subsidiary, Lee's Pharm (Hong Kong) Limited, has entered into an exclusive licensing agreement with US-based biotechnology firm 1cBio, Inc. to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1191","BK1587","00950","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145691069","title":"Trump Unveils Midterm Strategy: Tax Cuts and \"MAHA Movement\" Take Center Stage, Targeting Pharma and Processed Food Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=1145691069","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145691069?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:44","pubTimestamp":1788961466,"startTime":"0","endTime":"0","summary":"President Trump has stepped up his campaign efforts ahead of the November midterm elections, adopting a familiar playbook of self-promotion that he has long relied upon. Despite approval ratings...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159151","BK1161","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535781","title":"Everest Medicines Unit Enters Supply, Distribution Cooperation Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535781","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535781?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:26","pubTimestamp":1788960412,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) unit Everest Medicines (China) entered into a strategic cooperation framework agreement with Hasten Biopharmaceutical.The contract is for the supply, distribution, and rel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","01952","MDCO","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2473716301.USD","LU2272731600.USD","BK1161","HK0000320264.USD","IE00B5TLWC47.USD","IBBQ","MEDX","06978","02696","LNGR","BK4585","LU2322448791.USD","HK0000306685.HKD","LU1992135399.USD","IBB","HK0000306701.USD","HK0000165453.HKD","159992","LU2272731865.HKD","HK0000320223.HKD","PPH","BK4588","LU1992135472.HKD","LU2272731782.SGD","LU2322448957.HKD","BK1574","XPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113083232","title":"Everest Medicines Forms Strategic Alliance with Hissen for China Market Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1113083232","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113083232?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956296,"startTime":"0","endTime":"0","summary":"Everest Medicines (01952) has announced the signing of a strategic cooperation framework agreement with Hissen on September 9, 2026, under which both parties have agreed to establish a framework for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179497303","title":"Genfleet-B Repurchases 75,000 Shares for HK$1.96 Million on September 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1179497303","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179497303?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:14","pubTimestamp":1788956052,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that on September 9, 2026, the company spent HK$1.9608 million to repurchase 75,000 shares.The buyback transaction reflects the company's ongoing capital management...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939","02595","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173908290","title":"HBM Holdings' Strategic Partner Secures $225M Series A, Launches Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=1173908290","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173908290?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:18","pubTimestamp":1788952700,"startTime":"0","endTime":"0","summary":"HBM Holdings (02142) has announced that its partner company Solstice Oncology (Solstice) has successfully completed a $225 million Series A funding round and officially commenced operations. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587460","title":"HBM Partner Solstice Oncology Launches Phase 2 Trial of Porustobart in Neoadjuvant MSS Stage II-III Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587460","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587460?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952514,"startTime":"0","endTime":"0","summary":"HBM partner Solstice Oncology launches Phase 2 trial of porustobart in neoadjuvant MSS stage II-III colon cancerHBM Holdings’ partner Solstice Oncology launched with a USD 225 million Series A to adva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL71K3Mm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666163587","title":"Harbour Biomed Partner, Solstice Oncology, Announces $225 Million Series a Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666163587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666163587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:12","pubTimestamp":1788952368,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUAC6DRXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666976587","title":"Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2666976587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666976587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582914","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582914","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582914?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:45","pubTimestamp":1788950714,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase cancellation at HKD 20.82-21.38Zylox-Tonbridge filed a next-day disclosure return reporting an on-market buyback of 53,500 H s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3Z32VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02190","BK1100","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782105","title":"UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782105","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143782105?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:03","pubTimestamp":1788940980,"startTime":"0","endTime":"0","summary":"UBS has released a research report indicating that first-half results among Chinese pharmaceutical stocks were mixed, with five of the nine rated companies exceeding market expectations. These...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","HK0000165453.HKD","BK1521","IE00BZ08YT58.USD","BK1589","IE00B3M56506.USD","01177","02096","BK1191","IE00BZ08YR35.GBP","BK1593","BK1583","BK1161","01530","BK1515","BK1574","03933","01477","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144997108","title":"Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1144997108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144997108?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940815,"startTime":"0","endTime":"0","summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","688192","159938","09939","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112577285","title":"BOC International sees pharma sector earnings recovery as industry enters a reversal cycle","url":"https://stock-news.laohu8.com/highlight/detail?id=1112577285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112577285?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924637,"startTime":"0","endTime":"0","summary":"The pharmaceutical sector's interim reports for the first half of 2026 have been fully released, revealing resilient overall growth with structural improvements continuing to unfold, according to BOC...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159200143","title":"HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1159200143","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159200143?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924624,"startTime":"0","endTime":"0","summary":"VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.According to the company's recently disclosed first-half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1141","KCAI","01873","BK4585","BK1574","CDMO","VXUS","BK1191","BK4588","BK4139","BK1576"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":7,"totalSize":223,"code":"91000000","status":"200"}]}}